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Abstract: Hematologic malignancies are cancers that develop in the blood, bone
marrow, and lymph nodes. Hematopoietic stem cell transplantation (HSCT) is a critical
therapeutic approach that contributes to offer a potential cure for hematologic cancers and
other hematologic disorders by replacing abnormal bone marrow with healthy bone marrow
components to help bone marrow function recovery. Peripheral blood is the primary resource
for collecting hematopoietic stem cells (HSCs). The collection yield of HSCs is critical for
successful transplantation. Few articles have discussed this topic that the collection of stem
cells not only from healthy donors but also from donors with a hematologic or nonhematologic malignancy who likewise be in danger of mobilization failure. Therefore, our
goal of this paper is to study the collection efficiency of obtaining HSCs. Correlations were
measured by computing Spearman’s correlation coefficients. Trends were measured using
the Jonckheere-Terpstra test. Differences in groups were measured using the Mann-Whitney
U test. An all subsets selection model was built to compare to the model built with a

purposeful variable selection method. We employed sensitivity analysis to compare the
models and find the factors that influence the efficient collection. Our results showed that
many factors contribute to an efficient collection (r2 = 0.6). However, all but one of these
factors correlated very poorly with collection efficiency. It was the predicted total number of
CD34+ progenitor cells that correlated most strongly with predicting collection efficiency.
Our results showed that the patient's CD34+ cells could keep up at a sufficient level even
after large volume apheresis. Also, adding or deduct drug (plerixafor) usage could cause the
patient’s CD34+ level to increase or decrease. Overall, these discoveries will help to
determine the mobilizing drug usages when harvesting HSCs.
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Study Background
Hematologic Malignancies
Hematologic malignancies are cancers begin in the bone marrow that affect the blood,
bone marrow, and lymph nodes. They account for 9.5% of new cancer diagnoses in the
United States.1 Although hematologic malignancies are one of the leading causes of death
across the world, the survival rates of patients have improved at population level 10-year
survival based on recent progress in the treatment of hematologic malignancies. 2 There are
three types of hematopoietic malignancies; leukemia, lymphoma, and myeloma. Leukemia is
a type of hematopoietic cancer that affects blood-forming tissues which begin in the bone
marrow and induces large amounts of abnormal blood cells. It accounts for 2.5% of all
cancers worldwide. It affects all age groups, especially in children age 0-14, and older adults
over 65 years old.1 In the United States, the estimated number of new patients diagnosed with
leukemia in 2018 is 60,300 patients and the number of deaths is 24,370 patients.2
Approximately 11% are diagnosed under age 20 and 21% are diagnosed over age 65.2 Also,
the incidence is higher in Caucasians than in African Americans and Hispanics. The overall
incidence rate increases slowly, as treatment advances. There are four main types of
leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic
lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) affecting both
children and adults.1,3 ALL is more common in children that represent 15% of leukemias.1,3
In comparison, AML is the most common type of leukemia in adults which accounts for
about 30% of all leukemias.1,3 CLL accounts for about 30% of leukemia. It usually affects
older adults.1,3 CML is a rare type of leukemia, it accounts for 2 % to 3% of leukemias.1,3
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Lymphoma develops from lymphocytes residing in lymphoid tissue outside of the marrow.
Lymphomas are broadly separated into Hodgkin lymphoma (HL), and non-Hodgkin
lymphomas (NHL). HL occurs more often in younger adults age 15 to 30 and older adults
over age 55.1,4 The incidence of HL is about 3 per 100,000 in the United States.1,4 The 5-year
relative survival rate for patients diagnosed with HL is about to 86%.4 The incidence rate of
NHL in the United States is 2.1%.1,5 The 5-year relative survival rate for patients diagnosed
with NHL is about 71%.1,5 Myeloma is a plasma cell malignancy that accounts for
approximately 10% of the hematological malignancies.1 The incidence of myeloma is about
6.5 per 100,000 people per year in the United States.1,6 It usually occurs around the age of 60.
The five-year survival rate is about 49%.1,6 Hematologic malignancies have a devastating
effect on a person that age ranges from children to the old groups. Moreover, it has a large
negative impact on a person’s physical, mental, and economic health.
Hematologic Malignancies Treatment
The treatment of hematologic malignancies remains a challenge. Treatment varies
based on the types or subtypes of hematologic malignancies. Chemotherapy, radiotherapy,
immunotherapy, and stem cell transplantation are the well-established treatments for these
diseases. Chemotherapy uses anti-cancer drugs to destroy rapidly growing cancer cells in the
body. The role of chemotherapy play depends on the type of cancer or how advanced it is. It
gives patients with curative intent, or it prolongs survival or to reduce symptoms.7,8 Most
chemotherapy kills cancer cells rapidly by dividing cells that are most susceptible to the
drug. The major advantage of chemotherapy is it can travel all over the body and attack
vulnerable cells, whereas surgery and radiation are more likely to focus on one area. The
2

disadvantages of chemotherapy include side effects and the resistance of the chemical agents.
Radiotherapy kills cancer cells by using high doses of radiation. Radiation only targets a
certain part of the body based on the location of the tumor, while chemotherapy targets
cancerous cells throughout the body. The main disadvantages of radiation therapy include
damage to surrounding tissues and breakdown at the entry of the beam.10 Immunotherapy
uses the body’s immune system to fight cancer by considering the differences between
normal and cancerous cells and attack the cancer cells without harming normal cells. 11 HSCT
is a critical therapeutic approach that contributes to offer a potential cure for hematologic
cancers and other hematologic disorders by replacing abnormal bone marrow with healthy
bone marrow components to help bone marrow functions recovery.12 HSCT transplant
healthy hematopoietic stem cells (HSCs) in patients from bone marrow, umbilical cord
blood, or peripheral blood.13-15 Three main types of hematopoietic cell transplantation:
autologous, allogeneic and syngeneic. In autologous transplantation, the patients’ own HSCs
are used. In allogeneic transplantation, the HSCs come from a donor.13,14 In syngeneic
transplantation, the donor and the recipient are identical twins.13,14 HSC harvest is the
principal method for obtaining the cells that are transplanted in the bone marrow.15 Bone
marrow transplantation harvests HSCs directly from the pelvic bone of a person and then
infused into another person or the same person under general anesthesia.17 Nowadays, bone
marrow is mainly used in allogeneic HSCT. However, bone marrow harvest has a higher risk
and relatively low yield. Therefore, using the peripheral blood stem cell (PBSC) as a stem
cell source could be an optimal option.17 Umbilical cord blood is another HSC source that
blood is taken from the placenta after childbirth.22 Umbilical cord blood transplantation can
treat patients by harvesting and administrating stem cells quickly with fewer infections, and
3

lower rates of Graft vs host disease.12 However, umbilical cord blood transplant has higher
rates of disease relapses and delayed engraftment. Also, umbilical cord blood transplantation
can’t meet the needs of allogeneic transplantation for adults.12 Peripheral blood stem cell
transplantation (PBSCT) replaces destroyed blood-forming stem cells. From 2003, over 65%
of the HSCT is used mobilized PBSCs.18 PBSC harvests are easier and appealing than bone
marrow harvests.18 Moreover, the benefits of PBSCT include the recipient of PBSCs shows
less risk of graft failure, and the donors of PBSCT recover more rapidly, experience less
pain, and have no increased risk of cancer, autoimmune disease, or thrombosis. 20, 21 Now, a
majority of autologous and allogeneic transplants are performed with PBSC, there is a special
interest in optimizing their collection.
Peripheral Blood Stem Cell Mobilization and Collection Efficiency
Mobilization uses medications to stimulate the HSCs to exit the bone marrow and
move into the peripheral blood.22 Numerous factors with distinctive kinetics and efficiencies
induce peripheral blood stem cell mobilization.18,25 Commonly perceived regimens include
development factors like granulocyte-state animating variable (G-CSF), chemotherapy, and
plerixafor.26 Blends of growth factors that can have significant synergistic effects and can
deliver grafts with quantitative as well as subjective differences.18,25 G-CSF is a dominant
mobilizer that intensifies release serine proteases and hematopoietic stem cells from the bone
marrow.18,25 Plerixafor is a novel mobilization agent that stimulates the mobilization of stem
cells to the peripheral blood by preventing the combination of stromal cell-derived factor-1alpha (SDF-1) and C-X-C chemokine receptor type 4 (CXCR4).18,25 CD34+ is a useful
marker for progenitor hematopoietic stem cells that correlate with the collection yields in the
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peripheral blood.18, 25 The minimal dose of 2×102 cells/kg is required for proper engraftment,
while the optimal numbers are 4 to 5×106 CD34+ cells/kg.18, 25 Mobilization with
combinations of agents G-CSF alone, or with plerixafor accelerate PB CD34+ cells
circulating.18 Monitoring agents and combination agents during stem cell mobilization are
useful for identifying endangered patients who fail to collect a sufficient number of HSCs.
Transfusion sufficient CD34+ cell is critical for HSCT that the success can be measured like
engraftment, mortality. Collection efficiency (CE) is the ratio of the collection yield (CY) of
HSCs and the total number of HSCs circulating in the Peripheral blood.27 Aside from the
outcome, collection efficiency (CE) is a core parameter that can be utilized to measure the
cell separator’s ability to maximize the collection of PBSCs. Despite the fact that improved
technical increase efficient collections and application of PBSC transplantation have slowly
begun to expand, investigating CE is still at the starting stage. Thus, evaluating the agents,
understanding the mechanism of mobilization, and optimizing CE are fundamental to prevent
mobilization failure.
Public Health Significance
Hematologic malignancies patients have a high mortality rate. HSCT is a widely used
and crucial therapeutic strategy for improving overall survival for patients with
hematological malignancies.18 Poor mobilization response has become a significant obstacle
in HSCT, particularly in autologous patients. Ongoing investigations have demonstrated that
a higher portion of HSCs is related to better results. Therefore, the collection of an adequate
number of HSCs for reestablishing the bone marrow work plays a decisive rule.18 The datadriven analysis using the HSC data in this study can predict the CYs based on both precollection and collection factors. Results from our analysis can be utilized as hypothesis5

generating for the rule in structuring future safety and quality control guidelines which puts a
demanding task on the transplant establishment and reduce the incidence of mobilization
failure of HSCT. In the long run, our study also has the potential to improve HSCT treatment
and reduce the incidence of mobilization failure of HSCT among hematologic malignancies
patients.
Specific Aims
The objective of this research is to review the outcomes from patients who
experienced multiday collections by apheresis to evaluate the effect of mobilization regimes
on the CY of PBSC. First, we utilized Spearman’s correlation coefficients to measure the
correlations. Then, trends were measured using the Jonckheere-Terpstra Test. Moreover,
differences in groups were measured using the Mann-Whitney U test. To obtain the model of
the relationship between the analytic factors and CE, we utilized all subsets regression.
Purposeful variable selection was then used to build a model. Third, we compared the all
subsets selection model to the obtained purposeful variable selection model to get a final
selected model. Finally, we assessed the appropriateness and strength of the final selected
model using sensitivity analysis.
The specific aims are as follows:
1. Identifying vital sign factors associated with CE.
2. Conducting all subsets regression and purposeful variable selection to build
models.
3. Comparing model performance by sensitivity analysis.
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Methods
Data Summary
In this study, we used the patient who underwent large volume apheresis records. The
data is retrieved from a Quality Assurance project.34,35 This database is hosted by Wexner
Medical Center, Ohio State University, between November 2011 and July 2014.34,35 Data
included de-identified electronic patient records from Wexner Medical Center. 484 patients
underwent 683 leukapheresis procedures for the collection of hematopoietic stem cells. 283
(58.5%) are male, and 201(41.5%) are females. The mean age of patients is 53.7 years.34,35
Descriptive measures of factors are shown as below:
Table 1. Descriptive measure of factors
Factor
Age (years)
Height (ln)
Weight (kg)
Absolute lymphocyte
count (× 109 /𝐿)
Absolute segmented
neutrophil count (×
109 /𝐿)
Absolute lymphocyte
count (× 109 /𝐿)
Absolute monocyte
count (× 109 /𝐿)
Relative neutrophil
count (× 109 /𝐿)
Relative lymphocyte
count (× 109 /𝐿)
Relative monocyte
count (× 109 /𝐿)
Total blood volume
(ml)
White blood cell
count (× 109 /𝐿)
Hematocrit (%)
Platelet count (×
109 /𝐿)
Processed blood
volume (ml)

Mean
53.77
51.88
86.67
62.64

Median
57.00
65.00
85.20
60.00

SD
13.12
14.84
3.52
1.38

95% CI
(46.27; 59.22)
(49.63; 67.29)
(76.50; 94.00)
(59.82; 70.58)

50.18

51.00

15.13

(48.48; 54.88)

57.69

50.00

14.26

(49.19; 52.26)

50.18

47.00

13.30

(46.27; 51.88)

37.29

32.00

10.14

(36.82; 37.76)

39.50

44.00

13.30

(38.11; 61.36)

34.90

42.00

11.65

(39.50; 44.60

5197.00

5131.00

8.39

(4903.02; 5204.00)

38.00

36.00

12.29

(28.76; 39.82)

41.99
103.9

42.15
98.00

3.99
37.16

(39.50; 44.61)
(77.01; 108.49)

20781

20524

335.97

(19817.14;
25667.29)
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Minimum
anticoagulant ratio
Maximum
anticoagulant ratio
Product, collection
volume
Product, CD34+ cells
per ml
Product, CD34+ total
cell yield (CD34+×
106 /𝑘𝑔)
Prediction, CD34+
cells per ml
Prediction, CD34+
total cell yield
(CD34+× 106 /𝑘𝑔)
CD34 percentage of
viable leukocytes (%)
Collection
efficiency(%)

13.05

12.00

1.34

(11.82; 15.19)

13.48

14.00

1.31

(12.01; 17.34)

1338.00

2197.00

7.29

(1143.74; 2772.04)

2194.00

1330.00

163.69

(1274.58; 2875.60)

6.59

4.82

0.41

(3.64; 7.83)

2279.00

1483.00

133.81

(1163.29; 2747.04)

6.60

4.83

1.19

(3.35; 8.58)

38.05

36.30

12.12

(36.62; 39.48)

56.09

47.27

30.14

(43.72; 59.12)

Inclusion/ Exclusion criteria: From the patient records, our study population was
identified based on the following criteria: (1) Only records with a diagnosis history of
multiple myeloma (MM), NHL, acute leukemia, or HL. Autologous donors included patients
with MM (N = 236), NHL (N = 118), HL (N = 27), AML (N = 8), amyloidosis (N= 5), germ
cell tumor (N = 1) and healthy volunteers (N = 89). The minimum target collection goal was
2.5 x 106 CD34+ cells/kg by performing 683 leukapheresis procedures. Mobilization
regimens included G-CSF alone (N = 227), plerixafor alone (N = 5), G-CSF and plerixafor
(N = 353), G-CSF and chemotherapy (N = 66), and G-CSF and plerixafor and chemotherapy
(N = 32). Pre-collection laboratory results included absolute and relative differentials of
segmented neutrophils, lymphocytes, and monocytes, hematocrit, and platelet count. The
minimum platelet count was 30,000×106/L and minimum hematocrit was 24% for both
autologous and allogeneic donors. Anticoagulant (AC) ranged from 8:1 to 15:1. Patients
without complete information were excluded.
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Data cleaning: Observations with NULL value for height, weight, white blood cell
(WBC), operator, absolute segmented neutrophil count, absolute lymphocyte count, absolute
monocyte count, relative neutrophil count, relative lymphocyte count, relative monocyte
count, hematocrit, platelet count, minimum anticoagulant ratio, maximum anticoagulant
ratio, prediction CD34+ cells per ml, prediction CD 34+ total cell yield, product CD34+ cells
per ml, product CD 34+ total cell yield, CD34+ percentage of viable leukocytes. Patients’
records with any missing information were omitted from our analysis.
Study population: The average age of all patients is 53.77 years. 283 (58.5%) were
male, and 201 (41.5%) were female. Patients with MM, HL, NHL, AML, and germ cell
tumor and healthy volunteers were included. Our final data consisted of cleaned de-identified
patients’ records by using an individual identifier (variable Patient_SK). The data also
included age, gender, height, weight, white blood cell, operator, absolute segmented
neutrophil count, absolute lymphocyte count, absolute monocyte count, relative neutrophil
count, relative lymphocyte count, relative monocyte count, hematocrit, platelet count,
minimum anticoagulant ratio, maximum anticoagulant ratio, prediction CD34+ cells per ml,
prediction CD 34+ total cell yield, product CD34+ cells per ml, product CD 34+ total cell
yield, CD34+ percentage of viable leukocytes, calculated CE. Appendix I lists the all
predictors.
Statistical Analysis
The analysis was performed using the R statistical software package, version 4.0.2.
Factors were analyzed collectively from all procedures, from procedures performed on
single-day collectors and the first procedure of multiday collectors, and from multiday
collectors only. Factors were further analyzed after categorizing patients into three groups
9

based on increasing CEs: poor (CE < 50th percentile, N = 318), normal (CE between 50th
and 80th percentiles, N = 191), and good (CE > 80th percentile, N = 127). Percentiles were
selected based on targets relative to the generally accepted minimum target collection goal (2
x 106 CD34+ cells/kg).36 Poor allogeneic CE patients may still have enough HSCs for one
transplant. Good autologous CE patients may still have enough HSCs for one transplant if
they do not achieve a minimum 2.5 x 106 CD34+ cells/kg, which promotes the rapid
engraftment of neutrophils and platelets.37 Correlations were measured by computing
Spearman’s correlation coefficients. Trends were measured using the Jonckheere-Terpstra
test. Differences in groups were measured using the Mann-Whitney U test. All subsets
regression and purposeful variable selection were applied to obtain of the model of the
relationship between the analytic factors and CE. Mallow’s Cp, Akaike’s Information
Criteria (AIC), Receiver Operating Characteristic (ROC) curve were then utilized to compare
the model performance. Collection product (CP) volume is used to determine the CY. The
CP volume is used to determine the CY. Collection efficiency is calculated using the
following formula29-33:
𝑐𝑒𝑙𝑙𝑠
𝐶𝐷34+ 𝑘𝑔 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 × 𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)
𝐶𝑜𝑙𝑙𝑒𝑐𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑(𝜇𝐿) × 𝑃𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑎𝑙𝑏𝑙𝑜𝑜𝑑 𝐶𝐷34+ 𝑐𝑒𝑙𝑙𝑠/𝜇𝐿 × 10

The proposed formula includes input parameters such as patients’ body weight and total
volume processed, which had been tested by several studies that it would accurately predict
the CE.60-64 Nonetheless, there is no universal formula that has been developed to precisely
calculate the CE across various institutions. Also, in order to make sure all-important factors
being tested out, we left the input parameters in the formula in our dataset. Calculated CE
was added as new variable on the dataset.
10

Spearman’s Correlation Coefficient
Spearman’s correlation coefficient was employed to test the strength of how well the
variables relate or associate with each other.38,39 The spearman’s correlation coefficient is a
nonparametric measurement of the strength of the linear relationship which was first
formulated by Charles Spearman in 1904.38 Spearman correlation coefficient is calculated by
applying the formula40,41:
6 ∑𝑛𝑖=1 𝑑𝑖2
𝜌 =1−
𝑛(𝑛 2 − 1)
Where 𝑑𝑖 denotes the margin of each pair value, n denotes Spearman rank pair values.
We often use a hypothesis test to decide whether reject or does not reject 𝐻0 at the significant
level, where
𝐻0 : variable X and variable Y are mutually independent.
𝐻1 : There is either a positive or a negative correlation between variable X and variable Y.
A positive connection coefficient demonstrates a positive connection between the two
variables, while a negative relationship coefficient indicates a negative relationship.
Regardless of whether the correlation coefficient is zero, a non-linear relationship may still
exist. At the point we are interested in the strength of relationship between risk factors and
CE more than direction, the Spearman’s correlation coefficient is suitable to use with the
sizes of measurement for the data. Connection coefficients do not impact data about whether
one variable moves because of another.41 There is no endeavor to set up one variable as
dependent and the other one as independent. In this manner, association can be recognized
utilizing relationship coefficients not causal relationships.
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Jonckheere-Terpstra Test
Jonckheere-Terpstra test was used to determine if there is a statistically significant
trend between variables.42 The Jonckheere-Terpstra test is a nonparametric method for
ordered differences among classes which was first formulated by Terpastra and Jonckheere in
1952 and 1954.43 Jonckheere-Terpstra test is preferred when the alternative hypothesis takes
ordering into account. It tests the null hypothesis that the distribution of the variables does
not vary among classes and used to recognize the alternative hypothesis of ordered class
differences which can be shown as 𝐻0 : 𝜃1 = 𝜃2 = ⋯ = 𝜃𝑘 , 𝐻1 : 𝜃1 ≤ 𝜃2 ≤ ⋯ ≤ 𝜃𝑘 , where
𝜃𝑖 is the population median42,43.
Test statistic is defined as43
𝐽∗ =

𝐽 − 𝐸0 (𝐽)
√𝑉𝑎𝑟0(𝐽)

Where 𝐸0 (𝐽) is the expected value and 𝑉𝑎𝑟0 (𝐽) is the variance of the test statistic under null
hypothesis
𝑛 2 − ∑𝑖 𝑛𝑖2
𝐸0 (𝐽) =
4
𝑉𝑎𝑟0 (𝐽) =

𝐴
𝐵
𝐶
+
+
72 36𝑛(𝑛 − 1)(𝑛 − 2) 8𝑛(𝑛 − 1)

Where

𝐴 = 𝑛(𝑛 − 1)(2𝑛 + 5) − ∑ 𝑛𝑖 (𝑛𝑖 − 1)(2𝑛𝑖 + 5) − ∑ 𝑛𝑗 (𝑛𝑗 − 1)(2𝑛𝑗 + 5)
𝑖

𝑗

𝐵 = (∑ 𝑛𝑖 (𝑛𝑖 − 1)(𝑛𝑖 − 2)) ∑ 𝑛𝑗 (𝑛𝑗 − 1)(𝑛𝑗 − 2))
𝑖

𝑗
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𝐶 = ∑ 𝑛𝑖 (𝑛𝑖 − 1) (∑ 𝑛𝑗 (𝑛𝑗 − 1))
𝑖

𝑗

Where 𝑛𝑖 is the total number of outcomes in group i and 𝑛𝑗 is the total number of outcomes
in group j.
Mann-Whitney U test
One of the challenges is the data are not normally distributed. Hence, Mann-Whitney
U test was used to determine the difference between groups. The Mann-Whitney U test is a
one of the most powerful non-parametric tests for the differences coming from the same
population which was first formulated by Mann and Whitney in 1947.44 When the test
statistic gives good probabilities, the measure of reality is significant which is less at risk
compared to t-test when there exist some extreme values.44,45 Also, it can identify differences
in shape, spread, and medians.44,45 The null hypothesis (𝐻0 ) of the Mann‐Whitney U test
specifies that the two similar independent groups are from the same population. The Mann‐
Whitney test is based on the comparison of each observation 𝑥𝑖 from the first group with
each observation from the second group. The total number of possible paired comparisons is
(𝑛𝑥 𝑛𝑦 ), where 𝑛𝑥 is the number of observations in the first group and 𝑛𝑦 the number of
observations in the second. If the two groups have the same median, then each observation in
the first group has an equal chance of being greater or smaller than each observation in the
second group. In technical terms,45
𝐻0 : 𝑝(𝑥𝑖 > 𝑦𝑖 ) =

1
2

𝐻0 : 𝑝(𝑥𝑖 > 𝑦𝑖 ) ≠

1
2
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The null hypothesis is rejected if one group is significantly larger than the other group.
The test statistic is,45

𝑧=

𝑛𝑥 𝑛𝑦
2
𝜎𝑈

𝑈−

|𝑧| =

|𝑈𝑥 + 𝑈𝑦 |
𝜎𝑈

Where
𝑈𝑥 = 𝑛𝑥 𝑛𝑦 +

𝑛𝑥 (𝑛𝑥 + 1)
− 𝑅𝑥
2

𝑈𝑦 = 𝑛𝑥 𝑛𝑦 +

𝑛𝑦 (𝑛𝑦 + 1)
− 𝑅𝑦
2

Where 𝑛𝑥 is the number of observations in the first group, 𝑛𝑦 is the number of observations
in the second group, 𝑅𝑥 is the sum of the ranks of the first group and 𝑅𝑦 is the sum of the
ranks of the second group. If the absolute value of the calculated z is larger or equal to the
tabulated z value, the null hypothesis is rejected.
All Subsets Selection
All subsets regression aims to find the most ideal fit model from all possible subset
models that meet Mallow’s Cp, 𝑅2 , Bayesian Information Criteria (BIC) etc. which were first
formulated by Hocking and Leslie in 1967.46 We applied the best subset regression to obtain
with a reasonable and helpful regression model by including all variables that actually predict
the outcome. All subsets selection gives better prediction precision than forward stepwise
selection and lasso, over an assortment of problems.46 To begin with, identify all possible
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regression models from the potential mixes of the candidate variables. Then, determine the
model that has the lowest Mallow’s Cp, lowest BIC and largest 𝑅 2 . Interactions of risk
factors then are checked, and the significance are assessed. Mallow’s Cp is the criteria to
access the fit of a regression model by comparing the parameters of the full model and a
smaller model and finding the errors which first proposed by Mallows in 1964.49 The formula
is defined as:49
𝐶𝑝 =

𝑆𝑆𝐸𝑝
+ 2𝑝 − 𝑛
𝑀𝑆𝐸𝑝

Where p is the number of parameters, 𝑆𝑆𝐸𝑝 is the error sum of squares, 𝑀𝑆𝐸𝑝 is the mean
squared error.
BIC is another model selection criterion which first proposed by Schwartz in 1978. 51
It estimates the validity of a model by Bayesian setup. The formula is defined as:50
𝐵𝐼𝐶 = 𝑘𝑙𝑛(𝑛) − 2ln (𝐿̂ )
Where k is the number of parameters, n is the number of observations, 𝐿̂ is the maximized
value of the likelihood function of the model.
The adjusted 𝑅2 measure the coefficient of determination and are utilized to
determine the predictability of the variables.46 Mallow’s Cp measures bias and prediction
error. MSE estimates the average of the squares of the error.46 When choosing the best
subset, we are looking for the highest adjusted 𝑅2 as the adjusted 𝑅 2 only increases when
the added variables improve the model, not by chance alone.46 While 𝑅2 increases as the
number of variables increase. When Cp=p, Mallow’s Cp is not a good choice for selecting
the best model.46 When Cp is large, important variables need to be identified first, while,
when Cp nears p, the smallest Cp and few variables should be selected.46 Later, a validation
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set approach was employed by randomly assign 50% of the data set for training and 50% for
testing. Validation set approach is cross-validation technique that estimates a model error by
holding out a subset of the data during fitting.46 By employing this method, the best model is
the one with the lowest mean squared error (MSE).47 If the model does not correspond to the
previously chosen model by Mallow’s Cp, BIC or adjusted 𝑅2 , the 5-fold cross validation
approach to improve the holdout method. In k-fold cross validation, data set is split into k
disjoint subsets equally and repeat the holdout method for k times. One of the subsets is used
as test set, and k-1 subsets are used as training set. Then, the performance of the test sets is
measured. The best model would give the least MSE. The all subsets selection model can be
expressed as a linear combination of the predictors:
𝑔(𝜇) = 𝛽0 + 𝛽1 𝑋1 + 𝛽2 𝑋2 + ⋯ + 𝛽𝑘 𝑋𝑘
Purposeful Variable Selection
We applied the purposeful variable selection method for best subset selection to build
a logistic regression model. We used logistic regression to measure the association of
covariates with binary outcome. Binary classification was used to classify CE into two
groups on the basis of its mean value, whether CE is greater than the mean (1) or not (0).
The accompanying seven stages depict a technique for choosing variables that we call
deliberate determination. The reasoning behind the strategy is that it follows the means that
many applied agents utilize while analyzing a bunch of information and afterward
constructing a multivariable relapse model. Hosmer and Lemeshow proposed the purposeful
selection of variables method that not only select statistically significant covariates, but also
possible confounders.60 This method could be an alternative way that has not been examined
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with a few examples. There are seven steps of purposeful selection variables method to build
a multivariable regression model:
1. Initial screening: the purposeful selection starts by univariate regression analysis for
each variable. Conduct a contingency table analysis for categorical variables. Any
variable that has significant univariate test results is chosen as a candidate for further
analysis based on the Wald test or likelihood ratio test and p-value cutoff point of 0.20.25.
2. Reduced model: fit the multivariable model containing the variables that are
significantly identified in step 1, perform backward variable selection to remove the
insignificant variables if p-value greater than 0.05 or 0.1.
3. Comparing: compare the significant variables to the larger and the smaller model to
identify the notable covariates or confounding variables and add them back to the
model if necessary.
4. Fit a preliminary main effects model: any variable not chosen for the original
multivariate model is added back to the model in step 3, with critical covariates and
confounders held before. Significance is evaluated at p<0.05-0.2. This step can be
useful in recognizing variables that are not identified because of the insignificant
result but make a significant contribution with other variables together.
5. Fit a main effects model: check the linearity of the continuous variables that are
added back in step 4 in the logistic regression model by Locally Weighted Scatterplot
Smoothing (Lowess). Then, revise the model function if necessary.
6. Fit a preliminary final model: check for interactions in the model and if there are
important interaction terms left in the model.
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7. Final model: check the model fitting by Hosmer-Lemeshow (HL) statistics. If it is
good, it should be the final model.
Sensitivity Analysis
Sensitivity analysis plays a crucial rule to assess the robustness of the statistical
methods which includes model selection, classification, comparison, etc. It can also be
utilized to figure out which subset of input variables are attributed to most of the output
variance. Sensitivity analysis is a broad definition that the approach type and the purpose are
mainly depending on the modelling and study aim. In order to compare the all subsets
selection model and the purposeful variable selection model, AIC and ROC curve were
utilized. AIC is an estimator of out-of-sample deviances which was first proposed by
Hirotugu in 1970.50 It measures the quality of each model and ranks them. Also, it is
perceived as an index for reporting the trade-off between fitting and parsimony of the model.
Take into account of time and economic costs, AIC is employed to find a simple model with
great explanatory predictive power.50 The selected best model is neither under-fit nor overfit. The formula is defined as:50
𝐴𝐼𝐶 = 2𝑘 − 2ln (𝐿̂ )
Where k is the number of estimated parameters in the model, 𝐿̂ is the maximum value of the
likelihood function for the model.
ROC curve is a measurement of model performance over the range of trade-offs
which plots the sensitivity versus 1-specificity. It plays a central role in assessing the ability
of models to figure out the true state of the variables, finding the ideal cut off points and
comparing the models that are built from the same data.52 The Area Under Curve (AUC) is
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an index of accuracy that the higher the area under curve the better the prediction of the
model.52

Results
Spearman’s Correlation Coefficient
The first objective in our analysis was to measure correlations. For this purpose, we
conducted Spearman’s correlation coefficient. We used the cor.test function in R to evaluate
the strength of relationship between two variables. The variables that correlated with CE are
shown in Table 2. For first or only procedure, CE weakly correlated with WBC, absolute
segmented neutrophil count, absolute lymphocyte count, absolute monocyte count, platelet
count, minimum anticoagulant ratio, maximum anticoagulant ratio, prediction CD34+ cells
per ml, prediction CD 34+ total cell yield, same for all procedures.

Table 2: Factors correlating with collection efficiency.
First Only Procedure
Number
Spearman’s
Coefficient
443
-0.107*

All Procedures
Number
636

Spearman’s
Coefficient
-0.056

White Blood Cell
Count

442

-0.427**

635

-0.399**

Absolute
Segmented
Neutrophil Count

434

-0.394**

624

-0.347**

Absolute
Lymphocyte Count

434

-0.269**

624

-0.252**

Absolute
Monocyte Count

434

-0.306**

624

-0.296**

Relative
Neutrophil Count

434

-0.098*

624

0.036

434

0.196**

624

-0.002

Factor
Age

19

Relative
Lymphocyte Count
Relative Monocyte
Count

434

0.103*

624

0.038

Hematocrit

438

-0.160**

631

-0.148**

Platelet Count

442

-0.272**

635

-0.237**

Minimum
Anticoagulant
Ratio

443

0.123**

636

0.127**

Maximum
Anticoagulant
Ratio

443

0.166**

636

0.145**

443

0.089

636

0.086*

443

0.063

636

0.159**

Product, CD34+
Total Cell Yield

443

0.091

636

0.166**

Prediction, CD34+
Cells per ml†

443

-0.149**

636

-0.193**

Prediction, CD34+
Total Cell Yield

443

-0.143**

636

-0.193**

CD34+ Percentage
of Viable
Leukocytes

443

0.171**

636

0.056

Operator

443

0.076

636

0.082

Product, Collection
Volume
Product, CD34+
Cells per ml†

*p < 0.05, **p < 0.01
†

These values reflect the total number of CD34+ cells from a sample of the patient’s blood prior to collection
(prediction) and from the collection bag (product).

Jonckheere-Terpstra Test and Mann-Whitney U Test
After evaluating the correlation relationship between variables, we proceed with the
Jonckheere-Terpstra test. We used jonckheere.test function to identify statistically significant
trends between variables. Mann-Whitney U test was utilized to determine the difference
between groups with the wilcox.test function in R. As shown in Table 3, these variables
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trended significantly between CE groups. For the first or only procedure, age, WBC, absolute
segmented neutrophil count, absolute lymphocyte count, absolute monocyte count, platelet
count, prediction CD34+ cells per ml, prediction CD 34+ total cell yield trended inversely
between CE groups. For all procedures, age, WBC, absolute segmented neutrophil count,
absolute lymphocyte count, absolute monocyte count, hematocrit, platelet count, prediction
CD34+ cells per ml, prediction CD 34+ total cell yield trends inversely between CE groups.
For first or only procedure, minimum anticoagulant ratio, maximum anticoagulant ratio had
direct trends, while for all procedures, minimum anticoagulant ratio, maximum anticoagulant
ratio, product CD34+ cells per ml, product CD 34+ total cell yield had direct trends. Patient
age only collectively trended inversely between CE groups: for all procedures there was no
difference between individual CE groups, and for only the first procedure poor collectors
tended to be older than good collectors (p = 0.048).

Table 3: How factors trend relative to correlation efficiency groups.
First Only Procedure
Number
Direction
443
Inverse*

All Procedures
Number
636

Significance
Inverse*

White Blood Cell
Count

442

Inverse***

635

Inverse***

Absolute
Segmented
Neutrophil Count

434

Inverse***

624

Inverse***

Absolute
Lymphocyte Count

434

Inverse***

624

Inverse***

Absolute
Monocyte Count

434

Inverse***

624

Inverse***

Relative
Neutrophil Count

434

No Trend

624

No Trend

434

No Trend

624

No Trend

Factor
Age
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Relative
Lymphocyte Count
Relative Monocyte
Count

434

No Trend

624

No Trend

Hematocrit

438

No Trend

631

Inverse**

Platelet Count

442

Inverse***

635

Inverse***

Minimum
Anticoagulant
Ratio

443

Direct*

636

Direct***

Maximum
Anticoagulant
Ratio

443

Direct**

636

Direct***

443

No Trend

636

No Trend

443

No Trend

636

Direct**

Product, CD34+
Total Cell Yield

443

Inverse***

636

Inverse***

Prediction, CD34+
Cells Per ml†

443

Inverse***

636

Inverse***

Prediction, CD34+
Total Cell Yield

443

Inverse***

636

Inverse***

CD34+ Percentage
of Viable
Leukocytes

443

No Trend

636

No Trend

Operator

443

No Trend

636

No Trend

Product, Collection
Volume
Product, CD34+
Cells per ml†

*

p < 0.05, **p < 0.01, ***p < 0.001

In Table 4, results of variables that affect CE were found in multiday collectors to
further explain correlation or trend discrepancies in CE between first or only procedures and
all procedures. The CP volume was highest on the first day. By the third collection day CY
was less than in the first two days of collection. The HSC percentage of viable leukocytes
significantly decreases with each collection day. With each collection day the relative

22

segmented neutrophil count increased whereas the relative lymphocyte and monocyte counts
decreased. Hematocrit also tended to fall with each collection, though not significantly
between each collection day. Overall, CE did not change in multiday collectors. No
correlation or trend was seen with TBV and processed blood volume. Mobilization with GCSF + chemotherapy results in a higher CE compared to all other regimens (p < 0.001).
Collection efficiencies were no different in pairwise comparisons of these other regimens.
There was no difference in CE with respect to gender and diagnosis used to perform the
procedure. These findings were consistent for all procedures, including the first or only
procedure. In multiday collectors, there was no change from day to day in the mobilization
regimen.

Table 4: Factors affecting CE in multiday collectors
Factor (Including
Overall Test
Significance)

Mean Rank Day 1
(N=181)

Mean Rank Day 2
(N=173)

Mean Rank Day 3
(N=22)

Comparison
Groups

White Blood Cell
Count*

173.91

199.24

224.07

Day 1 Vs. Day 2
Day 1 Vs. Day 3
Day 2 Vs. Day 3

Relative
Segmented
Neutrophil
Count***

162.98

201.37

237.26

Day 1 Vs. Day 2**
Day 1 Vs. Day 3**
Day 2 Vs. Day 3

Relative
Lymphocyte
Count***

221.14

156.86

109.52

Day 1 Vs. Day
2***
Day 1 Vs. Day
3***
Day 2 Vs. Day 3

Relative Monocyte
Count***

214.52

161.58

125.00

Day 1 Vs. Day
2***
Day 1 Vs. Day 3**
Day 2 Vs. Day 3

Hematocrit*

203.22

176.39

162.57

Day 1 Vs. Day 2
Day 1 Vs. Day 3
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Product, Collection
Volume***

Day 2 Vs. Day 3
Day 1 Vs. Day
2***
Day 1 Vs. Day 3**
Day 2 Vs. Day 3

226.54

155.42

135.64

Product, CD34+
Cells per ml**

185.31

188.74

104.70

Day 1 Vs. Day 2
Day 1 Vs. Day 3**
Day 2 Vs. Day 3**

Product, CD34+
Total Cell Yield**

190.89

183.56

99.82

Day 1 Vs. Day 2
Day 1 Vs. Day
3***
Day 2 Vs. Day 3**

CD34+ Percentage
of Variable
Leukocytes***

210.92

178.08

85.98
Day 1 Vs. Day 2*
Day 1 Vs. Day
3***
Day 2 Vs. Day 3**

*p < 0.05, **p < 0.01, ***p < 0.001

All Subsets Selection
After we analyzed the correlations, trends and differences, we proceeded with all
subsets selection to build a model. We used the regsubset function to perform best subset
selection in order to choose the best model. By investigating the values of Mallow’s Cp, BIC
and adjusted 𝑅2 . The best model according to Mallow’s Cp was 3, according to adjusted 𝑅 2
was 9 and, according to BIC was 3. By using the cross validation, the model with predictors
age, WBC, operator, platelet count, prediction CD34+ total cell yield, product CD34+ cell
per ml, product collection volume, product CD34+ total cell yield, processed blood volume
and mobilization was chosen. However, this model did not correspond with any of the
models chosen by using Mallow’s Cp, BIC or adjusted 𝑅2 values. So, we used the predict
function with a 5-fold cross validation approach. We observed that the model with 9
predictor variables: WBC, operator, prediction CD34+ total cell yield, product CD34+ cell
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per ml, product collection volume, product CD34+ total cell yield, CD34+ percentage of
viable leukocytes, processed blood volume, and mobilization was shown to have the lowest
test error. This model corresponded with the model that was chosen by the lowest BIC value.
Interactions of factors were not significant which were not included in the model. Utilizing
these significant factors, the base model was constructed as below:
𝐸(𝐶𝐸) = 0.804 + 0.016 × 𝑊ℎ𝑖𝑡𝑒 𝑏𝑙𝑜𝑜𝑑 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 + 0.057 × 𝑜𝑝𝑒𝑟𝑎𝑡𝑜𝑟
+ 0.001 × 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑
+ 0.001 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑐𝑒𝑙𝑙 𝑝𝑒𝑟 𝑚𝑙
+ 0.001 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑜𝑙𝑙𝑐𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 + 0.073 × 𝑀𝑜𝑏𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛
+ 0.001 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑 − 0.240 × 𝐶𝐷34
+ 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑙𝑒𝑢𝑘𝑜𝑐𝑦𝑡𝑒𝑠
+ 0.001 × 𝑃𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑 𝑏𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒
Purposeful Variable Selection
After conducting all subsets modeling, the purposeful variable selection was
conducted. Based on the mean value, CE was dichotomized into two groups: greater than the
mean (1) or not (0). A univariable logistic regression analysis was used to select the variables
from the univariate stage that have a p-value <0.25. The p-value threshold was chosen
because after carried out the analysis, we found over half of the variables had p-value greater
than 0.25. CD34+ total cell yield, product CD34+ cell per ml, product collection volume,
product CD34+ total cell yield, processed blood volume, platelet count, Hematocrit and
mobilization were included in our model. For multivariate logistic regression, p-value
threshold was chosen since none of the variables have p-value <0.10. Further, in order to
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check the scale of the continuous covariates, we employed Locally Weighted Scatterplot
Smoothing (Lowess) smoothed univariable logit. The plots showed linear increase for all
continuous variables. We then built the main effects model. The model was constructed as
below:
𝑙𝑜𝑔𝑖𝑡(𝑃𝑟(𝐶𝐸 > 𝑚𝑒𝑎𝑛(𝐶𝐸)))
= 2.077 + 0.048 × 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑
+ 0.903 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑐𝑒𝑙𝑙 𝑝𝑒𝑟 𝑚𝑙
+ 0.091 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑜𝑙𝑙𝑐𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 + 0.073 × 𝑀𝑜𝑏𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛
+ 0.74 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑 + 0.993 × 𝐻𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡
+ 0.324 × 𝑃𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑 𝑏𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 − 0.101 × 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑐𝑜𝑢𝑛𝑡
By adding interactions and assessing the significance using likelihood ratio test, the results
showed very poor interaction between product CD34+ cell per ml and product CD34+ total
cell yield. The model with interaction term was constructed as:
𝑙𝑜𝑔𝑖𝑡(𝑃𝑟(𝐶𝐸 > 𝑚𝑒𝑎𝑛(𝐶𝐸)))
= 2.077 + 0.048 × 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑
+ 0.903 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑐𝑒𝑙𝑙 𝑝𝑒𝑟 𝑚𝑙
+ 0.091 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑜𝑙𝑙𝑐𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 + 0.073 × 𝑀𝑜𝑏𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛
+ 0.74 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑 + 0.993 × 𝐻𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡
+ 0.324 × 𝑃𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑 𝑏𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 − 0.101 × 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑐𝑜𝑢𝑛𝑡
+ 0.009 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34 + 𝑐𝑒𝑙𝑙 𝑝𝑒𝑟 𝑚𝑙 × 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝐶𝐷34
+ 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑
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As the likelihood ratio test showed the p-value was 0.018. We rejected the null
hypothesis. The two models were significantly different. So, we chose the model with
interaction terms as the preliminary final model. Later, by Hosmer-Lemeshow (HL) test, pvalue was 0.066, the results did not reject the null hypothesis. We concluded the model with
interaction terms fitted the data.
Sensitivity Analysis
After building the models, we proceeded with sensitivity analysis. First, we looked at
the AIC value, for all subsets selection model the AIC value was 251.9698, while for the
purposeful variable selection model it was 273.2441. All subsets selection model
outperformed purposeful variable selection model. Therefore, all subsets selection model had
the better parsimonious fit. For all subsets selection model, the highest validation AUC was
0.8658 with sensitivity 0.9493 and specificity 0.4046 (Figure 1). The validation AUC value
applying the purposeful variable selection was 0.804, with sensitivity value 0.9958 and
specificity value 0.0246 (Figure 2). The all subsets selection model performed slightly better
than the purposeful variable selection model, having higher specificity for a given sensitivity,
and higher sensitivity for given specificity. Therefore, all subsets selection model was chosen
over purposeful selection model. The most significant factors were chosen based on all
subsets selection model (p < 0.05) are summarized in Table 5. By far the most important
predictor of CE was the prediction CD34+ total cell yield.
Figure 1. ROC for All subsets selection
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Figure 2. ROC for purposeful variable selection

Table 5. Factors that impact CE based on multiple regression analysis (N = 636)
Factor

Importance

Prediction, CD34+ Total Cell Yield

0.728***

Product, CD34+ Cells per ml

0.074***

Product, Collection Volume

0.048***

Mobilization Regimen

0.035***

Product, CD34+ Total Cell Yield

0.026***

CD34+ Percentage of Viable Leukocytes

0.022**

Processed Blood Volume

0.018**

Operator

0.015*
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White Blood Cell Count
*

0.012*

p < 0.05, **p < 0.01, ***p < 0.001

Upon further evaluation predicted CD34 total cell count yield alone was estimated to
fit a logarithmic curve (Figure 3) (r2 =.868, p < .001) and to significantly predict the CE (β =
-.932, p < .001).

Figure 3. Correlation between CE and predicted CD34 total cell count yield

Discussion
A previous study on patients who underwent large volume apheresis records showed
that among all factors, absolute segmented neutrophil count, absolute lymphocyte count,
absolute monocyte count, platelet count, minimum anticoagulant ratio, maximum
anticoagulant ratio, prediction CD34+ cells per ml, prediction CD 34+ total cell yield had
been weakly associated with CE by Spearman’s correlation coefficient. At this point, we
were interested in investigating the trends and differences between groups. Tests showed
absolute segmented neutrophil count, absolute lymphocyte count, absolute monocyte count,
platelet count, prediction CD34+ cells per ml, prediction CD 34+ total cell yield trends
inversely between CE groups. A lower AC ratio helped platelets stabilize the buffy coat
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which allows for a more efficient collection53. Our results were consistent with the expected
findings of a direct relationship between the AC ratio and CE and an inverse relationship
between the platelet count and CE. In multiday collectors, however, both the AC ratio and
the platelet count maintained the same inverse relationship despite no effect on CE. Likely
the effects of mobilization on the platelet count were more pronounced in multiday
collectors. In patients mobilized with G-CSF platelet counts can begin to fall significantly
prior to collection54,55. There should be no effect from antiplatelet medications because they
were held well and throughout all procedures. The activation of neutrophils scintillates the
release of HSCs from within the bone marrow into the peripheral blood56. As the population
of HSCs increases the populations of other blood are expected to decrease so as to maintain
an efficient collection. While this effect was seen for all procedures the most efficient
collection was seen in the first or only procedure, which exhibited the highest HSC
percentage of viable leukocytes. This suggested that there was a point where a maximum
number of HSCs can be mobilized relative to their collection, which is further supported by
the fact that neither mobilization regimen nor CE changed with each collection. By the third
day of a daily series of collections the CY was significantly lower than in the first two days.
We found a more efficient collection with G-CSF + chemotherapy compared to all other
regimens. The same results were seen after analyzing the majority of the patients despite the
fact that in 66% of their collective procedures they were mobilized with G-CSF + plerixafor.
However, the addition of plerixafor to G-CSF + chemotherapy did not seem to result in
higher CEs. This may be due to the fact that both G-CSF and chemotherapy target HSC
niches in the endosteal and perivascular spaces as well as bone formation whereas plerixafor
directly targets HSCs without affecting either their niche or bone formation57. Some studies
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showed higher CYs with G-CSF + plerixafor compared to G-CSF + chemotherapy58,59. In
these studies, however, there was no difference in the median number of total CD34+
cells/kg. We used the median number of total CD34+ cells per volume (as opposed to per
weight) to calculate CYs and CEs. In doing so we found that the total CD34+ cells/ml
correlated with both the final collection yield of CD34+ cells and CE for all procedures.
Prediction CD34+ total cell yield, product CD34+ cell per ml, product collection volume,
product CD34+ total cell yield, processed blood volume and mobilization were important
factors that were included in both the all subsets selection model and the purposeful variable
selection model. These variables were important factors included in models accurately
predicted CE especially prediction CD34+ total cell yield. CD34+ percentage of viable
leukocytes was considered important in the all subsets selection model, while platelet count
and hematocrit were considered important in the purposeful variable selection model. AIC,
ROC curve and AUC resulted in a better prediction for predicting CE in all subsets selection
model compared to the purposeful variable selection model. The results of our analyses
simplified the prediction of an efficient collection by limiting pre-collection analytic
variables to just prediction CD34+ total cell yield, with very high correlation. When we
included all analytic variables into the regression model, we found a high 𝑅 2 ; however, due
to a number of competing interactions each variable correlated poorly with CE that can be
ignored. The prediction model produced allows for the surveillance of medication and
procedural factors associated with HSCT in order to observe which factors are most highly
associated with mortality. By understanding these variables, one can plan and implement
preventative measures to reduce the risk of hematologic malignancies that is so often
observed among patients.
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Our study has several limitations. The quality of the HSC data is poor since it is
retrospective and are not designed for the study. And the data has a high percentage of
missing values. Also, our study was limited by a mixed-effect regression analysis. However,
incorporating many analytic variables into a model that adjusts for numerous interactions
requires significant computer processing power. We simplified our approach by assuming
that discrepant analyses between first/only collection procedures and all procedures were a
result of patients who underwent multiple collections to achieve their prescribed collection
dose. As a result, changes in analytic variables from day to day in multiday collectors had no
effect on CE. Moreover, all the important factors that accurately predict CE may not be
captured in the data like participants’ race, apheresis machine, etc. Therefore, there is a high
probability of having excluded unmeasured confounding effects. Consequently, there could
be a potential for selection bias. The final equation may not necessarily reflect the true
model. To validate the research findings prospective studies applying our model would need
to be performed. Outcomes for CE groups would also need to be analyzed with respect to
achieving the prescribed collection dose.

Conclusion
In this thesis, we conducted the Spearman’s correlation coefficients to measure the
correlations, the Jonckheere-Terpstra test to measure the trends, and the Mann-Whitney U
test to measure the differences. An all subsets selection model was built to compare to the
model built with a purposeful variable selection method. The model difference could be the
result of the inherent differences of the two model approaches. The results suggested
prediction CD34+total cell yield alone was expected to be the most important variable in

32

determining CE. Prediction CD34+total cell yield may be best determined by the
mobilization regimen, which is directly responsible for the release of HSCs into the
peripheral blood. Different mobilization regimens and their side effects on the complete
blood cell count have synergistic and opposing effects on CE, which altogether must be taken
into account in conjunction with procedural characteristics in order to maximize CY. The CY
will be highest on the first day of a multiday collection, in part because of their availability in
the peripheral blood and decreased presence of available HSCs thereafter.
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Appendices
Appendix i
Summary of Predictors
Factor

Type

Number of

Number of factors

factors (First or

(All procedures)

only procedure)
Number of visits

Categorical

3

3

Age

Numeric

443

635

Gender

Binary

2

2

Height

Numeric

443

635

Weight

Numeric

443

635

Absolute lymphocyte

Numeric

434

624

Numeric

434

624

Numeric

434

624

Numeric

434

624

Numeric

434

624

Numeric

434

624

Numeric

434

624

AADX

Categorical

7

7

Total blood volume

Numeric

434

631

Mobilization

Categorical

6

6

count
Absolute segmented
neutrophil count
Absolute lymphocyte
count
Absolute monocyte
count
Relative neutrophil
count
Relative lymphocyte
count
Relative monocyte
count
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White blood cell count

Numeric

442

624

Operator

Categorical

7

7

Hematocrit

Numeric

438

631

Platelet count

Numeric

442

635

Processed blood

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

Numeric

443

636

volume
Minimum
anticoagulant ratio
Maximum
anticoagulant ratio
Product, collection
volume
Product, CD34+ cells
per ml
Product, CD34+ total
cell yield
Prediction, CD34+
cells per ml†
Prediction, CD34+
total cell yield
CD34 percentage of
viable leukocytes
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